Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy

• Egile Nagusiak: Jiayi Ye (Egilea), Bo Hou (Egilea), Fangmin Chen (Egilea), Shunan Zhang (Egilea), Muya Xiong (Egilea), Tianliang Li (Egilea), Yechun Xu (Egilea), Zhiai Xu (Egilea), Haijun Yu (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Cancer immunotherapy is impaired by the intrinsic and adaptive immune resistance. Herein, a bispecific prodrug nanoparticle was engineered for circumventing immune evasion of the tumor cells by targeting multiple immune resistance mechanisms. A disulfide bond-linked bispecific prodrug of NLG919 and...